
In this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.

In this article, Shipra Gandhi, MD, Pallawi Torka, MD, and Francisco J. Hernandez Ilizaliturri, MD summarize the current clinical development of these novel agents in lymphoid malignancies.

In this review, our authors discuss the mechanism of action and clinical development of various checkpoint inhibitors in lymphoma.

Published: December 9th 2015 | Updated:

Published: February 26th 2016 | Updated: